Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Abstract Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targetin...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-06-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-022-00688-4 |